ArticlePharmacological reports : PR2026
Tetrahydrocurcumin suppresses FcεRI- and MRGPRX2-mediated mast cell activation and attenuates peanut-induced anaphylaxis in an in vitro and in vivo study.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTetrahydrocurcumin (THC), a major reductive metabolite of curcumin, possesses improved chemical stability and anti-inflammatory properties. However, its direct effects on mast cell-mediated allergic responses remain poorly defined. We investigated whether THC suppresses FcεRI-dependent and selected IgE-independent mast cell activation and protects against peanut-induced anaphylaxis in vivo.
methodsPrimary murine bone marrow-derived mast cells and human LAD2 mast cells were stimulated through IgE/FcεRI crosslinking or MRGPRX2-related activation. Mast cell degranulation, cytokine production (CCL2, TNF, IL-6, and IL-13), and cytotoxicity were evaluated. The in vivo efficacy of orally administered THC was assessed in a mouse model of peanut-induced anaphylaxis.
resultsTHC dose-dependently inhibited IgE/FcεRI-mediated mast cell degranulation and suppressed inflammatory cytokine production without detectable cytotoxicity. Under the tested conditions, THC exhibited greater inhibitory activity than pemirolast potassium. THC also suppressed ionomycin- and MRGPRX2-mediated mast cell activation and remained effective when administered before or at the initiation of activation. In peanut-sensitized mice, repeated oral THC administration significantly reduced anaphylactic hypothermia and intestinal inflammatory responses.
conclusionTHC suppresses FcεRI-dependent and MRGPRX2-dependent pathways and attenuates peanut-induced anaphylactic responses in vivo. These findings support the potential of THC as a mast cell-modulating compound for allergic and anaphylactic disorders.
Indexed as
Identifiers
42734736What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.